Form 8-K

8-K — GLOBUS MEDICAL INC

Accession: 0001628280-26-032164

Filed: 2026-05-07

Period: 2026-05-07

CIK: 0001237831

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — gmed-20260507.htm (Primary)

EX-99.1 (gmed-q12026ex991.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: gmed-20260507.htm · Sequence: 1

gmed-20260507

0001237831FALSE00012378312026-05-072026-05-07

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 7, 2026

GLOBUS MEDICAL, INC.

(Exact name of registrant as specified in charter)

DELAWARE

001-35621 04-3744954

(State or other jurisdiction

of incorporation) (Commission

File Number) (IRS Employer

Identification No.)

2560 GENERAL ARMISTEAD AVENUE, AUDUBON, PA 19403-5214

(Address of principal executive offices) (Zip Code)

(610) 930-1800

(Registrant’s telephone number, including area code)

Not Applicable

(Former Address)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbols Name of exchange on which registered

Class A Common Stock, par value $.001 per share GMED New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02. Results of Operations and Financial Condition.

On May 7, 2026, Globus Medical, Inc. (the “Company”) issued a press release reporting, among other things, its sales and operating results for the three-month period ended March 31, 2026. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

In accordance with general instruction B.2 to Form 8-K, the information included in this Item 2.02, and the exhibit attached hereto, shall be deemed to be “furnished” and shall not be deemed to be “filed” with the Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

Exhibit No. Description

99.1

Press Release dated May 7, 2026

104 The cover page from this Current Report on Form 8-K, formatted as Inline XBRL.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GLOBUS MEDICAL, INC.

(Registrant)

Dated: May 7, 2026

/s/ KYLE R. KLINE

Kyle R. Kline

Chief Financial Officer

(Principal Financial Officer)

Senior Vice President

EX-99.1

Filename: gmed-q12026ex991.htm · Sequence: 2

Document

Exhibit 99.1

Globus Medical Reports First Quarter 2026 Results

AUDUBON, PA., May 7, 2026: Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the first quarter ended March 31, 2026.

First Quarter 2026:

•Worldwide net sales were $759.9 million, an increase of 27.0%, or an increase of 25.5% on a constant currency basis.

•Base business, excluding Nevro, net sales were $677.2 million, an increase of 13.2%, or an increase of 11.2% on a constant currency basis.

•GAAP net income for the quarter was $124.3 million.

•GAAP diluted earnings per share (“EPS”) was $0.90, an increase of 66.6%. Non-GAAP diluted EPS was $1.12, an increase of 64.7%.

“We’re off to a strong start in 2026 with 27% overall revenue growth and record first quarter earnings. Organic revenue grew over 13%, driven by share gains and procedural volume strength in core spine, while Enabling Technologies delivered against its pipeline and continued to expand its customer base,” commented Keith Pfeil, President and Chief Executive Officer. “Disciplined execution on manufacturing and supply chain initiatives, as well as structural cost actions, coupled with operating leverage on higher volumes, drove margin expansion in excess of sales growth, which we expect to favorably impact full-year results. Our strategic priority remains centered on achieving improved surgical outcomes through the Globus ecosystem, bringing together patient selection, surgical techniques with complementary implants and technology to drive the surgical procedure, through a closed-loop surgical intelligence system.”

“In the first quarter, US Spine continued to lead the way in growth for the organization, posting the third straight 10% growth quarter when compared to the same quarter of the prior year. This, paired with growth across all of our significant underlying businesses, drove record first quarter GAAP and non-GAAP net income and diluted earnings per share,” said Kyle Kline, Chief Financial Officer. “Nevro performed as expected as we continue to diligently work through the integration and adapt the business to Globus’ systems, processes, and metrics. Our total Company first quarter results represent an impressive beginning to 2026, reflecting the ongoing benefits of operating leverage, synergy realization, and financial discipline, positioning us well to deliver sustained earnings growth and value creation throughout the year.”

Worldwide net sales for the first quarter of 2026 were $759.9 million, an as-reported increase of 27.0% over the first quarter of 2025. U.S. net sales for the first quarter of 2026 increased by 25.0% compared to the first quarter of 2025. International net sales increased by 35.6% over the first quarter of 2025 on an as-reported basis and increased by 27.8% on a constant currency basis.

GAAP net income for the first quarter of 2026 was $124.3 million, an increase of 64.7% over the same period in the prior year. The increase in GAAP net income was primarily driven by higher sales of $161.7 million, with the sales from the acquisition of Nevro contributing $82.7 million. GAAP diluted EPS for the first quarter was $0.90, compared to $0.54 for the first quarter of 2025, an increase of 66.6%. Non-GAAP diluted EPS for the first quarter of 2026, which excludes, among other costs, amortization of intangibles, merger and acquisition-related costs, and restructuring-related costs, was $1.12, compared to $0.68 in the first quarter of 2025, an increase of 64.7%.

2026 Annual Guidance

The Company reaffirms its guidance for full-year 2026 revenue to be in the range of $3.18 billion to $3.22 billion and updates its guidance for non-GAAP fully diluted EPS to be in the range of $4.70 to $4.80 from the previous range of $4.40 to $4.50.

Conference Call Information

Globus Medical will hold a teleconference to discuss its 2026 first quarter results with the investment community at 4:30 p.m. Eastern Time today. Participants may access the conference call live via webcast on the Investors page of Globus Medical’s website at http://www.investors.globusmedical.com/news-events/events-webcasts.

To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. The audio archive will be available after the call on the Investor page of the Globus Medical website.

About Globus Medical, Inc.

Globus Medical, Inc. is a leading global musculoskeletal technology company dedicated to solving unmet clinical needs and changing lives. We innovate with inspired urgency, provide world-class education and clinical support, and advance care throughout spine,

orthopedic trauma, joint reconstruction, biomaterials and enabling technologies. Additional information can be accessed at www.globusmedical.com.

Non-GAAP Financial Measures

To supplement our financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), management uses certain non-GAAP financial measures. For example, non-GAAP Adjusted EBITDA, which represents net income before interest income, net and other non-operating expenses, provision for income taxes, depreciation and amortization, stock-based compensation expense, provision for litigation, merger and acquisition related costs, restructuring related costs, certain foreign currency acquisition-related impacts, bargain purchase gains, and gains and losses from strategic investments, is useful as an additional measure of operating performance, and particularly as a measure of comparative operating performance from period to period, as it is reflective of changes in pricing decisions, cost controls and other factors that affect operating performance, and it removes the effect of our capital structure, asset base, income taxes and interest income and expense. We no longer include acquisition of in-process research and development as an adjustment to non-GAAP Adjusted EBITDA. Our management also uses non-GAAP Adjusted EBITDA for planning purposes, including the preparation of our annual operating budget and financial projections. Provision for litigation represents costs incurred for litigation settlements or unfavorable verdicts when the loss is known or considered probable and the amount can be reasonably estimated, or in the case of a favorable settlement, when income is realized. Merger and acquisition related costs represents the change in fair value of business-acquisition-related contingent consideration; costs related to integrating recently acquired businesses, including but not limited to costs to exit or convert contractual obligations, severance, retention bonus, duplicative costs and information system conversion; and specific costs related to the consummation of the acquisition process such as banker fees, legal fees, and other acquisition related professional fees. Restructuring related costs include severance, retention bonus, accelerated stock-based compensation expense, legal and tax fees for legal entity reorganization and costs associated with consolidating facilities. We also adjusted for certain foreign currency impacts related to the acquisition costs and gains/losses on strategic investments within other assets as we believe these impacts are not a measure of our operating performance.

In addition, for the period ended March 31, 2026 and for other comparative periods, we are presenting non-GAAP net income and non-GAAP diluted EPS, which represent net income and diluted EPS excluding the provision for litigation, amortization of intangibles, merger and acquisition related costs, restructuring related costs, certain foreign currency impacts, gains and losses from strategic investments, bargain purchase gains, certain income tax net benefits and non-recurring tax adjustments, and the tax effects of all of the foregoing adjustments. We no longer include acquisition of in-process research and development as an adjustment to non-GAAP net income. We also present non-GAAP gross profit, which excludes the impacts of any inventory acquisition-related costs within cost of goods sold. The tax effect adjustment represents the tax effect of the pre-tax non-GAAP adjustments excluded from non-GAAP net income. The tax impact of the non-GAAP adjustments is calculated based on the consolidated effective tax rate on a GAAP basis, applied to the non-GAAP adjustments, unless the underlying item has a materially different tax treatment, in which case the estimated tax rate applicable to the adjustment is used. We believe these non-GAAP measures are also useful indicators of our operating performance, and particularly as additional measures of comparative operating performance from period to period as they remove the effects of the foregoing items, which we believe are not reflective of underlying business trends.

Additionally, for the period ended March 31, 2026 and for other comparative periods, we also define the non-GAAP measure of free cash flow as the net cash provided by operating activities, adjusted for the impact of restricted cash, less the cash impact of purchases of property and equipment. We believe that this financial measure provides meaningful information for evaluating our overall financial performance for comparative periods as it facilitates an assessment of funds available to satisfy current and future obligations and fund acquisitions. Furthermore, the non-GAAP measure of constant currency net sales growth is calculated by translating current year net sales at the same average exchange rates in effect during the applicable prior year period. We believe constant currency net sales growth provides insight to the comparative increase or decrease in period net sales, in dollar and percentage terms, excluding the effects of fluctuations in foreign currency exchange rates. We are also presenting base business sales and base Adjusted EBIDTA, excluding the contribution from the recently acquired Nevro Corp. (“Nevro”) and its subsidiaries. We believe these provide insight to how the Company is performing without the impact of our most recent acquisition.

Non-GAAP Adjusted EBITDA, non-GAAP net income, non-GAAP diluted EPS, non-GAAP gross profit, free cash flow, constant currency net sales growth, base business sales, excluding the contribution from the recently acquired Nevro, and day-adjusted basis sales are not calculated in conformity with GAAP. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for financial measures prepared in accordance with GAAP. These measures do not include certain expenses that may be necessary to evaluate our liquidity or operating results. Our definitions of these non-GAAP measures may differ from that of other companies and therefore may not be comparable. The tables included in this release reconcile the GAAP financial measures to the non-GAAP financial measures discussed above for the three months ended March 31, 2026.

We are unable to present a quantitative reconciliation of our expected fully diluted GAAP EPS to non-GAAP diluted EPS as we are unable to predict with reasonable certainty and without unreasonable effort the impact and timing of provision for litigation, amortization of intangibles, merger and acquisition-related costs, restructuring related costs, certain foreign currency acquisition-related impacts, bargain purchase gains, certain income tax net benefits from non-recurring tax adjustments, gains and losses from strategic investments,

and the tax effects of all of the foregoing adjustments. The financial impact of these items is uncertain and is dependent on various factors, including timing, and could be material to our Consolidated Statements of Income.

Safe Harbor Statements

All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, the risks and costs associated with health epidemics, pandemics and similar outbreaks, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, the successful integration of businesses that we have acquired or may acquire in the future, and other risks. For a discussion of these and other risks, uncertainties, and other factors that could affect our results, refer to the disclosures contained in our most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the “SEC”), including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our subsequent filings with the SEC. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. Except as may be required by applicable law, we undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof. As used herein, the “Company”, “Globus”, “Globus Medical”, “we”, “us”, and “our” refers to Globus Medical, Inc.

GLOBUS MEDICAL, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME

(unaudited)

Three Months Ended

March 31,

(In thousands, except per share amounts) 2026 2025

Net sales $ 759,854 $ 598,121

Cost of Sales and Operating expenses:

Cost of sales (exclusive of amortization of intangibles) 234,066 195,397

Research and development 36,510 33,062

Selling, general and administrative 297,775 242,799

Amortization of intangibles 29,526 28,802

Acquisition-related costs 6,377 1,057

Restructuring costs 5,212 —

Operating income/(loss) 150,388 97,004

Other income/(expense), net

Interest income/(expense), net 5,434 1,681

Foreign currency transaction gain/(loss) (2,113) 4,270

Bargain purchase gain 1,118 —

Other income/(expense) 2,247 713

Total other income/(expense), net 6,686 6,664

Income/(loss) before income taxes 157,074 103,668

Income tax provision/(benefit) 32,772 28,206

Net income/(loss) $ 124,302 $ 75,462

Other comprehensive income/(loss), net of tax:

Unrealized gain/(loss) on marketable securities (1,160) 315

Foreign currency translation gain/(loss) 218 4,379

Total other comprehensive income/(loss), net of tax (942) 4,694

Comprehensive income/(loss) $ 123,360 $ 80,156

Earnings per share:

Basic $ 0.92 $ 0.55

Diluted $ 0.90 $ 0.54

Weighted average shares outstanding:

Basic 135,364 136,757

Diluted 138,191 139,774

GLOBUS MEDICAL, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(unaudited)

March 31, December 31,

(In thousands, except share and per share values) 2026 2025

ASSETS

Current assets:

Cash and cash equivalents $ 560,950 $ 526,156

Short-term marketable securities 68,901 31,087

Accounts receivable, net of allowances $40,933 and $33,434, respectively

686,433 678,938

Inventories 772,602 759,277

Prepaid expenses and other current assets 60,228 65,426

Income taxes receivable 49,006 64,727

Total current assets 2,198,120 2,125,611

Property and equipment, net 557,139 564,452

Operating lease right of use assets 61,507 63,786

Long-term marketable securities 169,437 71,819

Intangible assets, net 720,845 745,064

Goodwill 1,438,733 1,435,033

Other assets 78,964 78,781

Deferred income taxes 214,810 218,215

Total assets $ 5,439,555 $ 5,302,761

LIABILITIES AND EQUITY

Current liabilities:

Accounts payable $ 103,658 $ 98,852

Accrued expenses 313,431 333,586

Operating lease liabilities 15,121 14,738

Income taxes payable 3,032 4,155

Business acquisition liabilities 20,874 19,513

Deferred revenue 26,347 27,655

Total current liabilities 482,463 498,499

Business acquisition liabilities, net of current portion 79,444 81,995

Operating lease liabilities 100,102 103,918

Deferred income taxes and other tax liabilities 24,658 23,756

Other liabilities 20,576 21,343

Total liabilities 707,243 729,511

Equity:

Class A common stock; $0.001 par value. Authorized 500,000,000 shares; issued and outstanding 113,236,099 and 112,625,126 shares at March 31, 2026 and December 31, 2025, respectively

113 113

Class B common stock; $0.001 par value. Authorized 275,000,000 shares; issued and outstanding 22,430,097 and 22,430,097 shares at March 31, 2026 and December 31, 2025, respectively

22 22

Additional paid-in capital 3,205,514 3,169,812

Accumulated other comprehensive income/(loss) 14,404 15,346

Retained earnings 1,512,259 1,387,957

Total equity 4,732,312 4,573,250

Total liabilities and equity $ 5,439,555 $ 5,302,761

GLOBUS MEDICAL, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

Three Months Ended

March 31,

(In thousands) 2026 2025

Cash flows from operating activities:

Net income $ 124,302 $ 75,462

Adjustments to reconcile net income to net cash provided by operating activities:

Bargain purchase gain (1,118) —

Depreciation and amortization 69,856 65,653

Provision for excess and obsolete inventory 4,960 5,960

Amortization of acquisition accounting fair value step up — 6,707

Stock-based compensation expense 12,617 13,206

Allowance for expected credit losses 5,277 3,206

Change in fair value of business acquisition liabilities 6,352 167

Change in deferred income taxes 7,962 509

(Gain)/loss on disposal of assets, net 2,449 2,613

Payment of business acquisition-related liabilities (2,273) (2,012)

Net (gain)/loss from foreign currency adjustment 98 (3,772)

(Increase) decrease in:

Accounts receivable (13,399) 22,603

Inventories (16,651) (7,587)

Prepaid expenses and other assets 6,942 4,534

Increase (decrease) in:

Accounts payable 5,082 (899)

Accrued expenses and other liabilities (24,668) (28,658)

Income taxes payable/receivable 14,576 19,608

Net cash provided by/(used in) operating activities 202,364 177,300

Cash flows from investing activities:

Purchases of marketable securities (146,393) (1,750)

Sales and maturities of marketable securities 8,243 174,238

Purchases of property and equipment (39,615) (36,103)

Acquisition of businesses, net of cash acquired and purchases of intangible and other assets (4,909) (5,000)

Net cash provided by/(used in) investing activities (182,674) 131,385

Cash flows from financing activities:

Payment of business acquisition-related liabilities (4,324) (3,890)

Net proceeds from exercise of stock options 25,961 11,223

Payments related to tax withholdings for share-based compensation (3,440) (2,293)

Repurchase of common stock — (190,451)

Repayment of senior convertible notes — (449,985)

Net cash provided by/(used in) financing activities 18,197 (635,396)

Effect of foreign exchange rates on cash (3,093) 3,539

Net increase/(decrease) in cash and cash equivalents 34,794 (323,172)

Cash and cash equivalents at beginning of period 526,156 784,438

Cash and cash equivalents at end of period $ 560,950 $ 461,266

Supplemental disclosures of cash flow information:

Income taxes paid, net $ 5,991 $ 7,199

Non-cash investing and financing activities:

Accrued purchases of property and equipment $ 10,517 $ 10,014

Supplemental Financial Information

Net Sales by Product Category:

Three Months Ended

March 31,

(In thousands) 2026 2025

Musculoskeletal Solutions $ 732,984 $ 575,932

Enabling Technologies 26,870 22,189

Total net sales $ 759,854 $ 598,121

Liquidity and Capital Resources:

March 31, December 31,

(In thousands) 2026 2025

Cash and cash equivalents $ 560,950 $ 526,156

Short-term marketable securities 68,901 31,087

Long-term marketable securities 169,437 71,819

Total cash, cash equivalents and marketable securities $ 799,288 $ 629,062

The following tables reconcile GAAP to non-GAAP financial measures.

Non-GAAP Adjusted EBITDA Reconciliation Table:

Three Months Ended

March 31,

(In thousands, except percentages) 2026 2025

Net income/(loss) $ 124,302 $ 75,462

Interest (income)/expense, net (5,434) (1,681)

Provision for income taxes 32,772 28,206

Depreciation and amortization 70,121 66,074

EBITDA 221,761 168,061

Stock-based compensation expense 12,614 13,052

Provision for litigation, net 134 (1,287)

Merger and acquisition-related costs (1)

6,441 1,106

Net (gain) loss from strategic investments (825) (61)

Non-cash acquisition-related foreign currency impacts (98) (3,772)

Restructuring costs 6,387 734

Bargain purchase gain (1,118) —

Adjusted EBITDA $ 245,296 $ 177,833

Net income/(loss) as a percentage of net sales 16.4 % 12.6 %

Adjusted EBITDA as a percentage of net sales 32.3 % 29.7 %

(1)Merger and acquisition-related costs represent certain costs associated with acquisitions. These costs, presented on a before-tax effect basis, are included in Non-GAAP Merger and Acquisition-related Costs Table.

Non-GAAP Merger and Acquisition-related Costs Table:

Three Months Ended

March 31,

(In thousands) 2026 2025

Amortization of inventory fair value step up $ — $ 49

Change in fair value of business acquisition liabilities 6,352 167

Employee-related costs (b)

25 —

Other acquisition-related costs (a)

64 890

Merger and acquisition-related costs $ 6,441 $ 1,106

(a)Primarily comprised of legal fees, advisory and consulting fees.

(b)Primarily comprised of severance, share based compensation and termination fees.

Non-GAAP Net Income Reconciliation Table:

Three Months Ended

March 31,

(In thousands) 2026 2025

Net income/(loss) $ 124,302 $ 75,462

Provision for litigation, net 134 (1,287)

Amortization of intangibles 29,526 28,802

Merger and acquisition -related costs (1)

6,441 1,106

Net gain/(loss) on strategic investments (825) (61)

Non-cash acquisition-related foreign currency impacts (98) (3,772)

Restructuring costs 6,387 734

Bargain purchase gain (1,118) —

Tax effect of adjusting items (9,853) (6,156)

Non-GAAP net income/(loss) $ 154,896 $ 94,828

(1) See footnote 1 to the Non-GAAP Adjusted EBITDA Reconciliation Table above for the detail for these costs.

Non-GAAP Gross Profit Reconciliation Table:

Three Months Ended

March 31,

(In thousands) 2026 2025

Net sales $ 759,854 $ 598,121

Cost of sales (exclusive of amortization of intangibles) 234,066 195,397

Amortization of intangibles 21,131 22,208

Gross Profit $ 504,657 $ 380,516

Amortization of inventory fair value step up — 49

Amortization of intangibles 21,131 22,208

Adjusted Gross Profit $ 525,788 $ 402,773

Gross Profit % of Net Sales 66.4 % 63.6 %

Adjusted Gross Profit % of Net Sales 69.2 % 67.3 %

Non-GAAP Diluted Earnings Per Share Reconciliation Table:

Three Months Ended

March 31,

(In thousands) 2026 2025

Diluted earnings per share, as reported $ 0.90 $ 0.54

Provision for litigation, net — (0.01)

Amortization of intangibles 0.21 0.21

Merger and acquisition -related costs (1)

0.05 0.01

Net (gain) loss from strategic investments (0.01) 0.00

Non-cash acquisition-related foreign currency impacts — (0.03)

Restructuring costs 0.05 0.01

Bargain purchase gain (0.01) —

Tax effect of adjusting items (0.07) (0.04)

Non-GAAP diluted earnings per share $ 1.12 $ 0.68

(1) See footnote 1 to the Non-GAAP Adjusted EBITDA Reconciliation Table above for the detail of these costs.

*Amounts may not add due to rounding.

Non-GAAP Free Cash Flow Reconciliation Table:

Three Months Ended

March 31,

(In thousands) 2026 2025

Net cash provided by operating activities $ 202,364 $ 177,300

Purchases of property and equipment (39,615) (36,103)

Free cash flow $ 162,749 $ 141,197

Non-GAAP Net Sales on a Constant Currency Basis Comparative Table:

Three Months Ended

March 31, Reported

Net Sales

Growth Currency

Impact on

Current

Period Net Sales Constant

Currency

Net Sales

Growth

(In thousands, except percentages) 2026 2025

United States $ 604,888 $ 483,857 25.0% $ — 25.0%

International 154,966 114,264 35.6% 8,974 27.8%

Total net sales $ 759,854 $ 598,121 27.0% $ 8,974 25.5%

Net Sales Reconciliation of the Nevro Acquisition Table:

Three Months Ended

March 31,

(In thousands) 2026 2025

Net Sales of Nevro products $ 82,675 $ —

Net Sales of base business 677,179 598,121

Total net sales $ 759,854 $ 598,121

Adjusted EBITDA Reconciliation of the Nevro Acquisition Table:

Three Months Ended

March 31,

(In thousands) 2026 2025

Adjusted EBITDA of the acquired Nevro subsidiaries $ 9,789 $ —

Adjusted EBITDA of base business 235,507 177,833

Total Adjusted EBITDA (1)

$ 245,296 $ 177,833

(1)See Non-GAAP Adjusted EBITDA Reconciliation Table above for calculation.

Investor Contact:

Brian Kearns

Senior Vice President, Corporate Development and Investor Relations

Phone: (610) 930-1800

Email: investors@globusmedical.com

www.globusmedical.com

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

May 07, 2026

Cover [Abstract]

Document Type

8-K

Document Period End Date

May 07, 2026

Entity Registrant Name

GLOBUS MEDICAL, INC.

Entity Incorporation, State or Country Code

Entity File Number

001-35621

Entity Tax Identification Number

04-3744954

Entity Address, Address Line One

2560 GENERAL ARMISTEAD AVENUE

Entity Address, City or Town

AUDUBON

Entity Address, State or Province

Entity Address, Postal Zip Code

19403-5214

City Area Code

(610)

Local Phone Number

930-1800

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Class A Common Stock, par value $.001 per share

Trading Symbol

GMED

Security Exchange Name

NYSE

Entity Emerging Growth Company

false

Entity Central Index Key

0001237831

Amendment Flag

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration